PL358221A1 - Zastosowanie antagonisty ośrodkowych receptorów kanabinoidowych do wytwarzania leków użytecznych doułatwiania zaprzestania używania tytoniu - Google Patents

Zastosowanie antagonisty ośrodkowych receptorów kanabinoidowych do wytwarzania leków użytecznych doułatwiania zaprzestania używania tytoniu

Info

Publication number
PL358221A1
PL358221A1 PL01358221A PL35822101A PL358221A1 PL 358221 A1 PL358221 A1 PL 358221A1 PL 01358221 A PL01358221 A PL 01358221A PL 35822101 A PL35822101 A PL 35822101A PL 358221 A1 PL358221 A1 PL 358221A1
Authority
PL
Poland
Prior art keywords
receptor antagonist
smoking cessation
cannabinoid receptor
preparing medicines
central cannabinoid
Prior art date
Application number
PL01358221A
Other languages
English (en)
Other versions
PL201685B1 (pl
Inventor
Jean Charles Blanchard
Francois Menard
Original Assignee
Sanofi-Synthelabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi-Synthelabo filed Critical Sanofi-Synthelabo
Publication of PL358221A1 publication Critical patent/PL358221A1/pl
Publication of PL201685B1 publication Critical patent/PL201685B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PL358221A 2000-02-09 2001-02-07 Zastosowanie N-piperydyno-5-(4-chlorofenylo)-1-(2,4-dichlorofenylo)-4-metylopirazolo-3-karboksyamidu do wytwarzania leków PL201685B1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0001682A FR2804604B1 (fr) 2000-02-09 2000-02-09 Utilisation d'un antagoniste des recepteurs aux cannabinoides centraux pour la preparation de medicaments utiles pour faciliter l'arret de la consommation de tabac
PCT/FR2001/000356 WO2001058450A2 (fr) 2000-02-09 2001-02-07 Utilisation d'un antagoniste des recepteurs aux cannabinoides centraux pour la preparation de medicaments utiles pour faciliter l'arret de la consommation de tabac

Publications (2)

Publication Number Publication Date
PL358221A1 true PL358221A1 (pl) 2004-08-09
PL201685B1 PL201685B1 (pl) 2009-04-30

Family

ID=8846875

Family Applications (1)

Application Number Title Priority Date Filing Date
PL358221A PL201685B1 (pl) 2000-02-09 2001-02-07 Zastosowanie N-piperydyno-5-(4-chlorofenylo)-1-(2,4-dichlorofenylo)-4-metylopirazolo-3-karboksyamidu do wytwarzania leków

Country Status (32)

Country Link
US (2) US6930122B2 (pl)
EP (1) EP1257275B1 (pl)
JP (2) JP2003522145A (pl)
CN (1) CN1250220C (pl)
AR (1) AR028505A1 (pl)
AT (1) ATE292467T1 (pl)
AU (1) AU781827B2 (pl)
BG (2) BG110386A (pl)
BR (1) BR0108126A (pl)
CA (1) CA2397262C (pl)
CZ (1) CZ296685B6 (pl)
DE (1) DE60109903T2 (pl)
DK (1) DK1257275T3 (pl)
EE (1) EE04836B1 (pl)
ES (1) ES2240416T3 (pl)
FR (1) FR2804604B1 (pl)
HU (1) HU225328B1 (pl)
IL (1) IL150710A0 (pl)
IS (1) IS6450A (pl)
MX (1) MXPA02007766A (pl)
NO (1) NO324521B1 (pl)
NZ (1) NZ519924A (pl)
PL (1) PL201685B1 (pl)
PT (1) PT1257275E (pl)
RS (1) RS50404B (pl)
RU (1) RU2257207C2 (pl)
SI (1) SI1257275T1 (pl)
SK (1) SK284952B6 (pl)
TW (1) TWI243677B (pl)
UA (1) UA72783C2 (pl)
WO (1) WO2001058450A2 (pl)
ZA (1) ZA200205317B (pl)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2804604B1 (fr) * 2000-02-09 2005-05-27 Sanofi Synthelabo Utilisation d'un antagoniste des recepteurs aux cannabinoides centraux pour la preparation de medicaments utiles pour faciliter l'arret de la consommation de tabac
US6462237B1 (en) * 2001-06-14 2002-10-08 Usv Limited Cyclodextrin stabilized pharmaceutical compositions of bupropion hydrochloride
CN1568429A (zh) 2001-08-13 2005-01-19 霍尼韦尔国际公司 使用上部层图形提供对晶片承载的半导体器件的电流控制
CA2478338A1 (en) 2002-03-08 2003-09-18 Signal Pharmaceuticals, Inc. Combination therapy for treating, preventing or managing proliferative disorders and cancers
NZ534757A (en) 2002-03-12 2006-07-28 Merck & Co Inc Substituted amides
AU2003215024B2 (en) 2002-03-26 2008-02-21 Merck Sharp & Dohme Corp. Spirocyclic amides as cannabinoid receptor modulators
CA2479744A1 (en) 2002-03-28 2003-10-09 Paul E. Finke Substituted 2,3-diphenyl pyridines
AU2003223510B2 (en) 2002-04-12 2008-05-08 Merck Sharp & Dohme Corp. Bicyclic amides
US6825209B2 (en) 2002-04-15 2004-11-30 Research Triangle Institute Compounds having unique CB1 receptor binding selectivity and methods for their production and use
EP1558252B1 (en) 2002-08-02 2007-10-10 Merck & Co., Inc. Substituted furo [2,3-b]pyridine derivatives
WO2004029204A2 (en) 2002-09-27 2004-04-08 Merck & Co., Inc. Substituted pyrimidines
US7129239B2 (en) 2002-10-28 2006-10-31 Pfizer Inc. Purine compounds and uses thereof
US7247628B2 (en) 2002-12-12 2007-07-24 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
KR20050088194A (ko) 2002-12-19 2005-09-02 머크 앤드 캄파니 인코포레이티드 치환된 아미드
US7329658B2 (en) 2003-02-06 2008-02-12 Pfizer Inc Cannabinoid receptor ligands and uses thereof
US7176210B2 (en) 2003-02-10 2007-02-13 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US7268133B2 (en) 2003-04-23 2007-09-11 Pfizer, Inc. Patent Department Cannabinoid receptor ligands and uses thereof
US7145012B2 (en) 2003-04-23 2006-12-05 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US20040224963A1 (en) * 2003-05-09 2004-11-11 Pfizer Inc Pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal
US20040224962A1 (en) * 2003-05-09 2004-11-11 Pfizer Inc Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss
DE602004031221D1 (de) * 2003-05-20 2011-03-10 Univ Tennessee Res Foundation Cannabinoidderivate, verfahren zu deren herstellung und deren verwendung
US7232823B2 (en) 2003-06-09 2007-06-19 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
EP1682494A4 (en) * 2003-10-30 2006-11-08 Merck & Co Inc ARALKYLAMINES AS MODULATORS OF CANNABINOID RECEPTORS
EP2343302A1 (en) 2004-07-12 2011-07-13 Cadila Healthcare Limited Tricyclic pyrazole derivatives as cannabinoid receptor modulators
US20060025448A1 (en) 2004-07-22 2006-02-02 Cadila Healthcare Limited Hair growth stimulators
CA2589483C (en) 2004-12-03 2013-10-29 Schering Corporation Substituted piperazines as cb1 antagonists
NZ569814A (en) * 2006-01-18 2011-10-28 Schering Corp Cannibinoid receptor modulators
WO2007121687A1 (en) * 2006-04-26 2007-11-01 Institute Of Pharmacology And Toxicology Academy Of Military Medical Sciences P.L.A. China 4-methyl-1h-diaryl pyrazole derivatives and their uses as medicament
CN101062919B (zh) * 2006-04-26 2012-08-15 中国人民解放军军事医学科学院毒物药物研究所 4-甲基-1h-二芳基吡唑衍生物及其作为药物的用途
US20070287734A1 (en) * 2006-06-09 2007-12-13 Auspex Pharmaceuticals, Inc. Preparation and utility of substituted pyrazole compounds with cannabinoid receptor activity
RU2477634C2 (ru) * 2006-06-16 2013-03-20 Теракос, Инк. Лечение психологических состояний с применением антагонистов m1-мускариновых рецепторов
AU2007312233B2 (en) * 2006-10-20 2012-09-20 Abbvie B.V. Micellar nanoparticles of chemical substances
US20100197564A1 (en) * 2007-04-19 2010-08-05 Schering Corporation Diaryl morpholines as cb1 modulators
CN101790521A (zh) * 2007-06-28 2010-07-28 英特维特国际股份有限公司 作为cb1拮抗剂的取代哌嗪
EP2548874A3 (en) * 2007-06-28 2013-05-15 Intervet International B.V. Substituted piperazines as CB1 antagonists
EP2095814A1 (de) * 2008-02-26 2009-09-02 Wolfgang J. Kox Medikamentengestützter Nikotinentzug
WO2010018856A1 (ja) * 2008-08-13 2010-02-18 持田製薬株式会社 カンナビノイド受容体関連疾患の予防／改善または治療剤
RU2533224C2 (ru) * 2010-07-21 2014-11-20 Мапикс Эс.Эй.Ар.Эл. Способ лечения зависимости от психоактивных веществ, алкоголизма и табакокурения и лекарственное средство для лечения зависимости от психоактивных веществ, алкоголизма и табакокурения
WO2013068371A1 (en) 2011-11-08 2013-05-16 Intervet International B.V. Soft chewable dosage form compositions of cannabinoid receptor type 1 (cb-1) antagonists
WO2014181357A1 (en) * 2013-05-09 2014-11-13 Council Of Scientific & Industrial Research Novel pyrazole derivatives with silicon incorporation
US20200035118A1 (en) 2018-07-27 2020-01-30 Joseph Pandolfino Methods and products to facilitate smokers switching to a tobacco heating product or e-cigarettes
US10897925B2 (en) 2018-07-27 2021-01-26 Joseph Pandolfino Articles and formulations for smoking products and vaporizers

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5780051A (en) * 1992-04-02 1998-07-14 Dynagen, Inc. Methods and articles of manufacture for nicotine cessation and monitoring nicotine use
FR2713225B1 (fr) * 1993-12-02 1996-03-01 Sanofi Sa N-pipéridino-3-pyrazolecarboxamide substitué.
FR2692575B1 (fr) * 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
US5596106A (en) * 1994-07-15 1997-01-21 Eli Lilly And Company Cannabinoid receptor antagonists
FR2758723B1 (fr) * 1997-01-28 1999-04-23 Sanofi Sa Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments
FR2765107B1 (fr) * 1997-06-26 2000-03-24 Sanofi Sa Utilisation d'un antagoniste specifique des recepteurs 5ht2 pour la preparation de medicaments utiles dans le traitement du syndrome d'apnee du sommeil
FR2789079B3 (fr) * 1999-02-01 2001-03-02 Sanofi Synthelabo Derive d'acide pyrazolecarboxylique, sa preparation, les compositions pharmaceutiques en contenant
FR2804604B1 (fr) * 2000-02-09 2005-05-27 Sanofi Synthelabo Utilisation d'un antagoniste des recepteurs aux cannabinoides centraux pour la preparation de medicaments utiles pour faciliter l'arret de la consommation de tabac

Also Published As

Publication number Publication date
SK284952B6 (sk) 2006-03-02
US6930122B2 (en) 2005-08-16
BG106946A (bg) 2003-05-30
RU2002118309A (ru) 2004-02-20
PL201685B1 (pl) 2009-04-30
WO2001058450A2 (fr) 2001-08-16
BR0108126A (pt) 2003-01-28
HUP0300237A2 (hu) 2003-07-28
FR2804604B1 (fr) 2005-05-27
BG65856B1 (bg) 2010-03-31
HU225328B1 (en) 2006-09-28
NZ519924A (en) 2005-01-28
AU781827B2 (en) 2005-06-16
JP2010018622A (ja) 2010-01-28
SK11292002A3 (sk) 2003-02-04
ES2240416T3 (es) 2005-10-16
CA2397262A1 (en) 2001-08-16
CN1406128A (zh) 2003-03-26
AR028505A1 (es) 2003-05-14
NO20023765D0 (no) 2002-08-08
AU3562001A (en) 2001-08-20
EE04836B1 (et) 2007-06-15
DE60109903D1 (de) 2005-05-12
HUP0300237A3 (en) 2003-09-29
MXPA02007766A (es) 2002-10-11
CZ20022698A3 (cs) 2002-11-13
YU59002A (sh) 2005-07-19
UA72783C2 (en) 2005-04-15
NO20023765L (no) 2002-10-09
US20050187253A1 (en) 2005-08-25
US20030087933A1 (en) 2003-05-08
EP1257275A2 (fr) 2002-11-20
DK1257275T3 (da) 2005-08-08
SI1257275T1 (en) 2005-10-31
ZA200205317B (en) 2003-09-04
EE200200439A (et) 2003-12-15
NO324521B1 (no) 2007-11-12
TWI243677B (en) 2005-11-21
HK1051140A1 (en) 2003-07-25
DE60109903T2 (de) 2006-02-09
CN1250220C (zh) 2006-04-12
BG110386A (en) 2009-09-30
JP2003522145A (ja) 2003-07-22
RU2257207C2 (ru) 2005-07-27
RS50404B (sr) 2009-12-31
ATE292467T1 (de) 2005-04-15
PT1257275E (pt) 2005-07-29
CZ296685B6 (cs) 2006-05-17
WO2001058450A3 (fr) 2002-04-25
EP1257275B1 (fr) 2005-04-06
CA2397262C (en) 2007-09-11
IS6450A (is) 2002-06-28
FR2804604A1 (fr) 2001-08-10
IL150710A0 (en) 2003-02-12

Similar Documents

Publication Publication Date Title
PL358221A1 (pl) Zastosowanie antagonisty ośrodkowych receptorów kanabinoidowych do wytwarzania leków użytecznych doułatwiania zaprzestania używania tytoniu
UA66900C2 (uk) Похідні піразолкарбонової кислоти, спосіб їх виготовлення, фармацевтична композиція, що їх містить
UA49056C2 (uk) Фармацевтична композиція для перорального застосування аміду n-піперидин-5-(4-хлорфеніл)-1-(2,4-дихлорфеніл)-4-метилпіразол-3-карбонової кислоти, його солей і сольватів та спосіб її отримання
ATE352552T1 (de) Substituierte pyrazole
CA2136893A1 (en) Substituted n-piperidino-pyrazole-3-carboxamide
HUP0300867A3 (en) Aryl substituted pyrazoles, triazoles and tetrazoles, and the use thereof and pharmaceutical compositions containing the compounds
MXPA03000059A (es) Derivados de pirazol.
JP2003522145A5 (pl)
HUP0303108A3 (en) Substituted pyrazoles and pharmaceutical compositions containing them
MXPA03001593A (es) Derivados de pirazola fusionada siendo inhibidores de quinasa de proteina.
IL167038A (en) Pyrazole derivatives, pharmaceutical compositions containing the same, use thereof in the manufacture of medicaments and intermediate for production thereof
EP1224173A4 (en) PYRAZOLE DERIVATIVES AS CANNABINOID RECEPTOR ANTAGONISTS
YU7804A (sh) Stabilni polimorf flibanserina,postupak za njegovo dobijanje u industrijskim razmerama i njegova primena za pripremanje lekova
FR2849032B1 (fr) Derive de 5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethyl-n -(piperidin-1-yl)-1h-pyrazole-3-carboxamide, sa preparation, son application en therapeuthique
CY1112078T1 (el) Χρηση των ανταγωνιστων του cb1 υποδοχεα για την παρασκευη ενος σκευασματος που θα χρησιμοποιηθει για τη θεραπεια των ηπατικων νοσων
WO2003082256A3 (fr) Traitement des dysfonctionnements sexuels a l'aide d'un antagoniste des recepteurs aux cannabinoides cb1
WO2001049651A3 (de) Aminomethyl-phenyl-cyclohexanonderivate
AU7865000A (en) Fused 1-(2,6-dichloro-4-trifluoromethylphenyl)-pyrazoles, the synthesis thereof and the use thereof as pesticides
MXPA04000953A (es) Derivados sustituidos del acido 5,6,6a,11b-tetrahidro-7-oxa-aza-benzo[c]fluoren-6-carboxilico como antagonista de nmda.
HU1000512D0 (en) 4,5-diaryl-3(2h)-furanone derivatives as cyclooxygenase-2 inhibitors, diaryl-oxaspirobicyclyc derivatives
HU0004052D0 (en) Improved process for the preparation of 1-(3'-chloro-2-tertier-butylamino)-propiophenone
GB0018662D0 (en) Novel process for the preparation of pyrazoles
IT250792Y1 (it) Boccaglio per erogatori di apparecchi respiratori subacquei.
TH62253A (th) การใช้เซ็นทรัลแคนนาบินอยด์รีเซพเตอร์แอนแทกโกนิสต์ เพื่อการเตรียมผลิตภัณฑ์ยาซึ่งใช้ประโยชน์เพื่อการช่วยให้เลิกสูบบุหรี่

Legal Events

Date Code Title Description
VDSO Invalidation of derivated patent or utility model

Ref document number: 385191

Country of ref document: PL

LAPS Decisions on the lapse of the protection rights

Effective date: 20100207